1Daly JS,,Kopasz A,Anandakrishnan R.Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplanta-tion recipients[].American Journal of Transplantation.2002
2Paya CV,Wilson JA,Espy MJ,et al.Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant pa-tients:a randomized,placebo-controlled trial[].The Journal of Infectious Diseases.2002
3Sarcinella,L,Mazzulli,T,Willey,B,Humar,A.Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients[].Journal of Clinical Virology.2002
4Lowance,D,Neumayer,H-H,Legendre,CM,Squifflet,J-P,Kovarik,J,Brennan,PJ,Norman,D,Mendez,R,Keating,MR,Coggon,GL.Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation[].The New England Journal of Medicine.1999
5Taber DJ,Ashcraft E,Baillie GM,et al.Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease[].Transplant Infectious Disease.2004
6Yango A,Morrisssey P,Zanabli A,et al.Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients[].Nephrology Dialysis Transplantation.2003
7Oldakowska-Jedynak U,Niewczas M,Ziolkowski J,et al.Cytomegalovirus infection as a common complication following liver transplantation[].Transplantation Proceedings.2003
8Anglicheau D,Lautrette A,Scieux C,et al.Efficacy and safety of lowering Immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study[].Nephrology Dialysis Transplantation.2003
9Temperton NJ.DNA vaccines against cytomegalovirus: current progress[].Inter J Antimicrobial Angents.2002
10Akalin E.Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis[].American Journal of Transplantation.2003
